Charles River Laboratories Return on Tangible Equity 2010-2024 | CRL

Current and historical return on tangible equity values for Charles River Laboratories (CRL) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Charles River Laboratories Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2024-09-30 $0.42B $-0.12B -192.71%
2024-06-30 $0.44B $-0.15B -144.35%
2024-03-31 $0.44B $-0.25B -107.12%
2023-12-31 $0.47B $-0.36B -88.10%
2023-09-30 $0.47B $-0.46B -72.39%
2023-06-30 $0.48B $-0.59B -81.86%
2023-03-31 $0.50B $-0.75B -96.82%
2022-12-31 $0.49B $-0.82B -133.70%
2022-09-30 $0.44B $-0.20B -93.71%
2022-06-30 $0.44B $-0.27B -86.35%
2022-03-31 $0.42B $-0.15B -80.88%
2021-12-31 $0.39B $-1.23B -90.88%
2021-09-30 $0.40B $-0.39B -649.18%
2021-06-30 $0.40B $-0.31B 788.06%
2021-03-31 $0.38B $0.21B 328.23%
2020-12-31 $0.36B $0.24B 1693.02%
2020-09-30 $0.30B $0.05B -885.29%
2020-06-30 $0.27B $-0.05B -425.10%
2020-03-31 $0.25B $-0.16B -274.79%
2019-12-31 $0.25B $0.02B -854.24%
2019-09-30 $0.23B $-0.07B -667.63%
2019-06-30 $0.22B $-0.16B -572.55%
2019-03-31 $0.23B $0.09B -576.10%
2018-12-31 $0.23B $0.00B -22700.00%
2018-09-30 $0.14B $-0.08B 320.47%
2018-06-30 $0.13B $-0.17B 127.72%
2018-03-31 $0.13B $0.24B 74.89%
2017-12-31 $0.12B $0.18B 98.20%
2017-09-30 $0.20B $0.15B 261.39%
2017-06-30 $0.18B $0.12B 404.40%
2017-03-31 $0.17B $0.05B 1081.97%
2016-12-31 $0.16B $-0.02B 209.46%
2016-09-30 $0.14B $0.03B 103.27%
2016-06-30 $0.14B $-0.00B 106.21%
2016-03-31 $0.16B $0.29B 82.89%
2015-12-31 $0.15B $0.23B 93.02%
2015-09-30 $0.15B $0.01B 77.23%
2015-06-30 $0.14B $0.22B 58.64%
2015-03-31 $0.13B $0.19B 53.85%
2014-12-31 $0.13B $0.34B 44.21%
2014-09-30 $0.12B $0.22B 41.70%
2014-06-30 $0.12B $0.20B 37.20%
2014-03-31 $0.11B $0.39B 31.28%
2013-12-31 $0.10B $0.33B 31.35%
2013-09-30 $0.10B $0.34B 31.51%
2013-06-30 $0.09B $0.33B 29.64%
2013-03-31 $0.10B $0.31B 31.84%
2012-12-31 $0.10B $0.31B 33.05%
2012-09-30 $0.11B $0.30B 38.60%
2012-06-30 $0.10B $0.28B 39.96%
2012-03-31 $0.10B $0.27B 41.11%
2011-12-31 $0.11B $0.24B 44.04%
2011-09-30 $-0.26B $0.24B -93.32%
2011-06-30 $-0.31B $0.28B -95.63%
2011-03-31 $-0.32B $0.24B -73.89%
2010-12-31 $-0.34B $0.37B -60.41%
2010-09-30 $0.02B $0.39B 3.72%
2010-06-30 $0.09B $0.75B 12.02%
2010-03-31 $0.11B $0.73B 15.34%
2009-12-31 $0.11B $0.71B 17.06%
Sector Industry Market Cap Revenue
Medical Medical Services $9.314B $4.129B
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $84.995B 10.55
Cencora (COR) United States $43.734B 16.44
DiDi Global (DIDIY) China $22.941B 0.00
Natera (NTRA) United States $20.871B 0.00
ICON (ICLR) Ireland $16.879B 15.03
Viatris (VTRS) United States $14.478B 4.46
Avantor (AVTR) United States $14.307B 21.45
Revvity (RVTY) United States $13.453B 23.37
BioMerieux (BMXMF) France $12.659B 0.00
CochLear (CHEOY) Australia $11.807B 0.00
Solventum (SOLV) United States $11.540B 0.00
Medpace Holdings (MEDP) United States $10.417B 29.35
Doximity (DOCS) United States $10.302B 60.64
HealthEquity (HQY) United States $8.212B 41.20
Sonic Healthcare (SKHHY) Australia $8.208B 0.00
Bausch + Lomb (BLCO) Canada $6.322B 29.43
Amplifon S.p.A (AMFPF) Italy $5.864B 29.89
Sotera Health (SHC) United States $3.759B 20.11
Organon (OGN) United States $3.719B 3.75
BrightSpring Health Services (BTSG) United States $2.967B 63.11
Surgery Partners (SGRY) United States $2.493B 28.42
Concentras Parent (CON) United States $2.491B 0.00
Ardent Health Partners (ARDT) United States $2.291B 0.00
GeneDx Holdings (WGS) United States $2.069B 0.00
Premier (PINC) United States $2.067B 10.76
PACS (PACS) United States $1.992B 0.00
Alignment Healthcare (ALHC) United States $1.969B 0.00
Ryman Healthcare (RYHTY) New Zealand $1.730B 0.00
GoodRx Holdings (GDRX) United States $1.711B 44.90
Teladoc Health (TDOC) United States $1.544B 0.00
Pediatrix Medical (MD) United States $1.224B 11.98
Progyny (PGNY) United States $1.208B 24.47
Embecta (EMBC) United States $1.161B 8.12
CareDx (CDNA) United States $1.102B 0.00
Establishment Labs Holdings (ESTA) $1.090B 0.00
AMN Healthcare Services Inc (AMN) United States $0.874B 5.91
QDM (QDMI) Hong Kong, SAR China $0.790B 20.69
Agilon Health (AGL) United States $0.775B 0.00
SBC Medicals (SBC) United States $0.649B 0.00
Auna S.A (AUNA) Luxembourg $0.492B 0.00
InnovAge Holding (INNV) United States $0.478B 0.00
DocGo (DCGO) United States $0.444B 16.73
Sonida Senior Living (SNDA) United States $0.441B 0.00
Enhabit (EHAB) United States $0.387B 33.48
Sera Prognostics (SERA) United States $0.275B 0.00
COMPASS Pathways (CMPS) United Kingdom $0.268B 0.00
LifeMD (LFMD) United States $0.212B 0.00
Biodesix (BDSX) United States $0.198B 0.00
Beauty Health (SKIN) United States $0.176B 0.00
Nutex Health (NUTX) United States $0.160B 0.00
ModivCare (MODV) United States $0.156B 8.44
MultiPlan (MPLN) United States $0.108B 0.00
Ascend Wellness Holdings (AAWH) United States $0.099B 0.00
So-Young (SY) China $0.093B 15.69
IceCure Medical (ICCM) Israel $0.052B 0.00
Singular Genomics Systems (OMIC) United States $0.050B 0.00
OncoCyte (OCX) United States $0.037B 0.00
NeueHealth (NEUE) United States $0.033B 0.87
Pheton Holdings (PTHL) China $0.027B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.023B 0.00
Co-Diagnostics (CODX) United States $0.023B 0.00
Oncology Institute (TOI) United States $0.016B 0.00
SeaStar Medical Holding (ICU) United States $0.009B 0.00
XWELL (XWEL) United States $0.008B 0.00
KindlyMD (KDLY) United States $0.007B 0.00
Intelligent Bio Solutions (INBS) United States $0.006B 0.00
BioNexus Gene Lab (BGLC) $0.005B 0.00
NewGenIvf Group (NIVF) Thailand $0.003B 0.00
ISpecimen (ISPC) United States $0.003B 0.00
Cano Health (CANOQ) United States $0.001B 0.00
Aclarion (ACON) United States $0.001B 0.00